How much revenue did Kuros Biosciences generate this year?
Kuros Biosciences has achieved a revenue of 33.56 M CHF this year.
Kuros Biosciences Revenue 2024
Kuros Biosciences Revenue
33.56 M CHF
Ticker
KURN.SW
ISIN
CH0325814116
WKN
A2ALS5
In 2024, Kuros Biosciences's sales reached 33.56 M CHF, a 86.61% difference from the 17.99 M CHF sales recorded in the previous year.
The Kuros Biosciences Revenue history
| YEAR | REVENUE (undefined CHF) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 33.56 | 84,83 |
| 2022 | 17.99 | 79,89 |
| 2021 | 13.82 | 72,86 |
| 2020 | 4.04 | 41,37 |
| 2019 | 2.56 | 81,18 |
| 2018 | 0.72 | 86,57 |
| 2017 | 0.53 | 5331,65 |
| 2016 | 1.06 | 2683,41 |
| 2015 | 0.14 | 19771,53 |
| 2014 | 1 | 2847,10 |
| 2013 | 1 | 2847,10 |
| 2012 | 1.1 | 2588,27 |
| 2011 | 1.57 | -963,06 |
| 2010 | 22.35 | 0,63 |
| 2009 | 9.11 | -261,91 |
| 2008 | 19.73 | -100,20 |
| 2007 | 35.88 | -11,73 |
| 2006 | 0.72 | -4395,83 |
| 2005 | 4.36 | -576,15 |
| 2004 | 4.11 | -513,14 |
Kuros Biosciences Revenue, EBIT, Net Income CH0325814116 · A2ALS5
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Kuros Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kuros Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kuros Biosciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Kuros Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Kuros Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Kuros Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kuros Biosciences’s growth potential.
Kuros Biosciences Revenue, Profit, and EBIT History
| Date | Kuros Biosciences Revenue | Kuros Biosciences EBIT | Kuros Biosciences Net Income |
|---|---|---|---|
| 2023 | 33.56 M CHF | -8.66 M CHF | -13.73 M CHF |
| 2022 | 17.99 M CHF | -9.85 M CHF | -14.6 M CHF |
| 2021 | 13.82 M CHF | -8.77 M CHF | -7.54 M CHF |
| 2020 | 4.04 M CHF | -11.68 M CHF | -11.52 M CHF |
| 2019 | 2.56 M CHF | -11.39 M CHF | -11.25 M CHF |
| 2018 | 715,000 CHF | -13.73 M CHF | -11.69 M CHF |
| 2017 | 534,000 CHF | -16.24 M CHF | -16.48 M CHF |
| 2016 | 1.06 M CHF | -21.35 M CHF | -19.74 M CHF |
| 2015 | 144,000 CHF | -4.22 M CHF | -5.78 M CHF |
| 2014 | 1 M CHF | -18.94 M CHF | -34.03 M CHF |
| 2013 | 1 M CHF | -22.59 M CHF | -30.83 M CHF |
| 2012 | 1.1 M CHF | -13.5 M CHF | -9.22 M CHF |
| 2011 | 1.57 M CHF | -19.71 M CHF | -18.78 M CHF |
| 2010 | 22.35 M CHF | -3.86 M CHF | -1.45 M CHF |
| 2009 | 9.11 M CHF | -27.24 M CHF | -24.83 M CHF |
| 2008 | 19.73 M CHF | -23.88 M CHF | -26.01 M CHF |
| 2007 | 35.88 M CHF | -8.3 M CHF | -6.88 M CHF |
| 2006 | 720,000 CHF | -35.09 M CHF | -34.55 M CHF |
| 2005 | 4.36 M CHF | -29.32 M CHF | -28.48 M CHF |
| 2004 | 4.11 M CHF | -25.14 M CHF | -23.22 M CHF |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 4.11 M CHF | -25.14 M CHF | -23.22 M CHF |
| 2005 | 4.36 M CHF | -29.32 M CHF | -28.48 M CHF |
| 2006 | 720,000 CHF | -35.09 M CHF | -34.55 M CHF |
| 2007 | 35.88 M CHF | -8.3 M CHF | -6.88 M CHF |
| 2008 | 19.73 M CHF | -23.88 M CHF | -26.01 M CHF |
| 2009 | 9.11 M CHF | -27.24 M CHF | -24.83 M CHF |
| 2010 | 22.35 M CHF | -3.86 M CHF | -1.45 M CHF |
| 2011 | 1.57 M CHF | -19.71 M CHF | -18.78 M CHF |
| 2012 | 1.1 M CHF | -13.5 M CHF | -9.22 M CHF |
| 2013 | 1 M CHF | -22.59 M CHF | -30.83 M CHF |
| 2014 | 1 M CHF | -18.94 M CHF | -34.03 M CHF |
| 2015 | 144,000 CHF | -4.22 M CHF | -5.78 M CHF |
| 2016 | 1.06 M CHF | -21.35 M CHF | -19.74 M CHF |
| 2017 | 534,000 CHF | -16.24 M CHF | -16.48 M CHF |
| 2018 | 715,000 CHF | -13.73 M CHF | -11.69 M CHF |
| 2019 | 2.56 M CHF | -11.39 M CHF | -11.25 M CHF |
| 2020 | 4.04 M CHF | -11.68 M CHF | -11.52 M CHF |
| 2021 | 13.82 M CHF | -8.77 M CHF | -7.54 M CHF |
| 2022 | 17.99 M CHF | -9.85 M CHF | -14.6 M CHF |
| 2023 | 33.56 M CHF | -8.66 M CHF | -13.73 M CHF |
Kuros Biosciences stock margins CH0325814116 · A2ALS5
The Kuros Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kuros Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kuros Biosciences.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Kuros Biosciences's sales revenue. A higher gross margin percentage indicates that the Kuros Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Kuros Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Kuros Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kuros Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kuros Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kuros Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Kuros Biosciences Margin History
| Kuros Biosciences Gross margin | Kuros Biosciences Profit margin | Kuros Biosciences EBIT margin | Kuros Biosciences Profit margin |
|---|---|---|---|
| 2023 | 84.83 % | -25.79 % | -40.9 % |
| 2022 | 79.89 % | -54.74 % | -81.15 % |
| 2021 | 72.86 % | -63.46 % | -54.59 % |
| 2020 | 41.37 % | -289.16 % | -285.22 % |
| 2019 | 81.18 % | -444.83 % | -439.36 % |
| 2018 | 86.57 % | -1,919.86 % | -1,635.38 % |
| 2017 | 84.83 % | -3,041.76 % | -3,086.89 % |
| 2016 | 84.83 % | -2,011.88 % | -1,860.89 % |
| 2015 | 84.83 % | -2,931.94 % | -4,016.67 % |
| 2014 | 84.83 % | -1,893.7 % | -3,402.6 % |
| 2013 | 84.83 % | -2,259 % | -3,083 % |
| 2012 | 84.83 % | -1,227.27 % | -838.18 % |
| 2011 | -963.06 % | -1,255.41 % | -1,196.18 % |
| 2010 | 0.63 % | -17.27 % | -6.49 % |
| 2009 | -261.91 % | -299.01 % | -272.56 % |
| 2008 | -100.2 % | -121.03 % | -131.83 % |
| 2007 | -11.73 % | -23.13 % | -19.18 % |
| 2006 | -4,395.83 % | -4,873.61 % | -4,798.61 % |
| 2005 | -576.15 % | -672.48 % | -653.21 % |
| 2004 | -513.14 % | -611.68 % | -564.96 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -513.14 % | -611.68 % | -564.96 % |
| 2005 | -576.15 % | -672.48 % | -653.21 % |
| 2006 | -4,395.83 % | -4,873.61 % | -4,798.61 % |
| 2007 | -11.73 % | -23.13 % | -19.18 % |
| 2008 | -100.2 % | -121.03 % | -131.83 % |
| 2009 | -261.91 % | -299.01 % | -272.56 % |
| 2010 | 0.63 % | -17.27 % | -6.49 % |
| 2011 | -963.06 % | -1,255.41 % | -1,196.18 % |
| 2012 | 84.83 % | -1,227.27 % | -838.18 % |
| 2013 | 84.83 % | -2,259 % | -3,083 % |
| 2014 | 84.83 % | -1,893.7 % | -3,402.6 % |
| 2015 | 84.83 % | -2,931.94 % | -4,016.67 % |
| 2016 | 84.83 % | -2,011.88 % | -1,860.89 % |
| 2017 | 84.83 % | -3,041.76 % | -3,086.89 % |
| 2018 | 86.57 % | -1,919.86 % | -1,635.38 % |
| 2019 | 81.18 % | -444.83 % | -439.36 % |
| 2020 | 41.37 % | -289.16 % | -285.22 % |
| 2021 | 72.86 % | -63.46 % | -54.59 % |
| 2022 | 79.89 % | -54.74 % | -81.15 % |
| 2023 | 84.83 % | -25.79 % | -40.9 % |
Kuros Biosciences Aktienanalyse
What does Kuros Biosciences do?
Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Kuros Biosciences's Sales Figures
The sales figures of Kuros Biosciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Kuros Biosciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Kuros Biosciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Kuros Biosciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Kuros Biosciences Stock
How much was the turnover of the company Kuros Biosciences compared to the previous year?
The revenue of Kuros Biosciences has increased by 86.61% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Kuros Biosciences?
The revenue of Kuros Biosciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Kuros Biosciences measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Kuros Biosciences so important for investors?
The revenue of Kuros Biosciences is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Kuros Biosciences pay?
Over the past 12 months, Kuros Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kuros Biosciences is expected to pay a dividend of 0 CHF.
What is the dividend yield of Kuros Biosciences?
The current dividend yield of Kuros Biosciences is .
When does Kuros Biosciences pay dividends?
Kuros Biosciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Kuros Biosciences?
Kuros Biosciences paid dividends every year for the past 0 years.
What is the dividend of Kuros Biosciences?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Kuros Biosciences located?
Kuros Biosciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Kuros Biosciences from 6/27/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
When did Kuros Biosciences pay the last dividend?
The last dividend was paid out on 6/27/2024.
What was the dividend of Kuros Biosciences in the year 2023?
In the year 2023, Kuros Biosciences distributed 0 CHF as dividends.
In which currency does Kuros Biosciences pay out the dividend?
The dividends of Kuros Biosciences are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Kuros Biosciences
Our stock analysis for Kuros Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kuros Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Kuros Biosciences Revenue
- Kuros Biosciences Net Income
- Kuros Biosciences P/E
- Kuros Biosciences P/S
- Kuros Biosciences EBIT
- Kuros Biosciences Dividend
- Kuros Biosciences Stocks
- Kuros Biosciences Market capitalization
- Kuros Biosciences Debt
- Kuros Biosciences Liabilities
- Kuros Biosciences Equity
- Kuros Biosciences AAQS
- Kuros Biosciences Employees
- Kuros Biosciences ROE
- Kuros Biosciences ROA
- Kuros Biosciences ROCE
